Pharmaceutical

FDA gives TSND-201 breakthrough therapy designation for PTSD

Transcend Therapeutics announced that the FDA has granted breakthrough therapy designation to TSND-201 to treat PTSD.

Jul 11, 2025 - 06:00
FDA gives TSND-201 breakthrough therapy designation for PTSD
Transcend Therapeutics announced that the FDA has granted breakthrough therapy designation to TSND-201 to treat PTSD.
Read the original article

Tags:

Previous Article

Modular manufacturing: The key to unlocking mRNA expansion?

Next Article

Enhancing solubility of targeted protein degraders: Better strategies for bioava...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy

Sanders takes aim at US drug prices of Novo’s Ozempic a...

Apr 27, 2024

Project Optimus: The evolution of dose optimisation in oncology

Project Optimus: The evolution of dose optimisation in ...

Mar 7, 2025

EC grants orphan drug status to Biodexa’s oral FAP treatment

EC grants orphan drug status to Biodexa’s oral FAP trea...

May 14, 2025